WallStreetZenWallStreetZen

NYSEMKT: NBY
Novabay Pharmaceuticals Inc Earnings & Revenue

OverviewEarnings
DividendOwnership

NBY past revenue growth

How has NBY's revenue growth performed historically?
Company
2.24%
Industry
151.46%
Market
17.61%
NBY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
NBY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
NBY's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

NBY earnings and revenue history

Current Revenue
$14.7M
Current Earnings
-$16.7M
Current Profit Margin
-113.4%

NBY Return on Equity

Current Company
-240.2%
Current Industry
-63.5%
Current Market
188%
NBY's Return on Equity (-240.2%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when NBY announces earnings.

NBY Return on Assets

Current Company
-126.7%
Current Industry
2.9%
NBY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

NBY Return on Capital Employed

Current Company
-202.69%
Current Industry
19.5%
NBY's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NBY vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
NBY$14.73M-$9.44M-$16.70M+3.32%N/A
CYCC$420.00k-$25.52M-$22.76M+22.87%N/A
QNRX$0.00-$8.58M-$8.69MN/AN/A
DRMA$0.00-$7.79M-$7.79MN/AN/A
CYTO$0.00-$2.31M-$4.30MN/AN/A
View Top Biotech Stocks

NBY earnings dates

Next earnings date
May 9, 2024

Novabay Pharmaceuticals Earnings & Revenue FAQ

What were NBY's earnings last quarter?

On Invalid Date, Novabay Pharmaceuticals (NYSEMKT: NBY) reported Q4 2023 earnings per share (EPS) of -$1.69, up 64.64% year over year. Total Novabay Pharmaceuticals earnings for the quarter were -$9.17 million. In the same quarter last year, Novabay Pharmaceuticals's earnings per share (EPS) was -$4.78.

If you're new to stock investing, here's how to buy Novabay Pharmaceuticals stock.

What was NBY's earnings growth in the past year?

As of Q2 2024, Novabay Pharmaceuticals's earnings has grown year over year. Novabay Pharmaceuticals's earnings in the past year totalled -$16.70 million.

What is NBY's earnings date?

Novabay Pharmaceuticals's earnings date is Invalid Date. Add NBY to your watchlist to be reminded of NBY's next earnings announcement.

What was NBY's revenue last quarter?

On Invalid Date, Novabay Pharmaceuticals (NYSEMKT: NBY) reported Q4 2023 revenue of $3.73 million up 2.31% year over year. In the same quarter last year, Novabay Pharmaceuticals's revenue was $3.64 million.

What was NBY's revenue growth in the past year?

As of Q2 2024, Novabay Pharmaceuticals's revenue has grown 2.24% year over year. This is 149.22 percentage points lower than the US Biotechnology industry revenue growth rate of 151.46%. Novabay Pharmaceuticals's revenue in the past year totalled $14.73 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.